Key factors in the rising cost of new drug discovery and development

Nature Reviews Drug Discovery

Volumn 3, Issue 5, 2004, Pages 417-429

  Dickson, Michael ^a   Gagnon, Jean Paul ^b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CELECOXIB; CENTRAL NERVOUS SYSTEM AGENTS; DIGOXIN; DIURETIC AGENT; FLUOXETINE; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC AGENT; NEUROLEPTIC AGENT; NEW DRUG; ROFECOXIB; SERTRALINE; SILDENAFIL; SULFONAMIDE; THALIDOMIDE;

CARDIOVASCULAR DISEASE; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INFECTION; INVESTMENT; MEDICAID; PATENT; PRESCRIPTION; PRIORITY JOURNAL; PROFIT; REVIEW; UNITED STATES;

EID: 2442482962     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1382     Document Type: Review

References (62)

1. Neumann, P. J. Evidence-based and value-based formulary guidelines. Health Affairs 23, 124-134 (2004).
2. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. American Heart Association [online], (2004).
3. P. L. 102-571, Title I, Section 103. The Prescription Drug User Fee Act of 1992.
4. Kaitin, K. Tufts Center for the Study of Drug Development News Release. [online], (2003).
5. Government Accounting Office. Effect of User Fees on Drug Approval Times, Withdrawal, and other Agency Activities. GAO report 02-958, Washington, September 2002 [online], (2002).
6. Kaufman, M. Decline in new drugs raises concerns. Washington Post November 17 (2002).
7. DiMasi, J. A. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69, 297-307 (2001).
8. Grabowski, H. The effect of pharmacoeconomics on company research and development decisions. PharmacoEconomics 11, 389-397 (1997).
9. DiMasi, J. A., & Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
10. Wardell, W. M., & Hassar, M., Anavekar, S. N. & Lasagna, L. The rate of development of new drugs in the United States, 1963 through 1975. Clin. Pharmacol. Ther. 24, 133-145 (1978).
11. Wardell, W. M., DiRaddo, J. & Trimble, G. Development of new drugs originated and acquired by United States-owned pharmaceutical firms, 1963-1976. Clin. Pharmacol. Ther. 28, 270-277 (1980).
12. Wardell, W. M., May, M. S. & Trimble, G. New drug development by United States pharmaceutical firms. Clin. Pharmacol. Ther. 32, 407-417 (1982).
13. Mattison, N., Trimble, G. & Lasagna, L. New drug development in the United States, 1963 through 1984. Clin. Pharmacol. Ther. 43, 290-301 (1988).
14. DiMasi, J. A., Bryant, N. R. & Lasagna, L. New drug development in the United States from 1963 to 1990. Clin. Pharmacol. Ther. 50, 471-486 (1991).
15. DiMasi, J. A. Success rates for new drugs entering clinical testing in the United States. Clin. Pharmacol. Ther. 58, 1-14 (1995).
16. DiMasi, J. A. New drug development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 69, 286-296 (2001).
17. Grabowski, H. & Vernon, J. The distribution of sales revenues from pharmaceutical innovation. PharmacoEconomics 18, S1, 21-32 (2000).
18. Grabowski, H. & Vernon J. A new look at the returns and risks to pharmaceutical R&D. Management Sci. 36, 804-821 (1990).
19. Joglekar, P. & Paterson, M. A closer look at the returns and risks of pharmaceutical R&D. J. Health Econ. 5, 153-177 (1986).
20. Grabowski, H., Vernon J. & DiMasi, J. Returns on research and development for 1990s now drug introductions. PharmacoEconomics 20, S3 11-29 (2002).
21. Grabowski, H. & Vernon, J. Effective patent life in pharmaceuticals. Intl J. Tech. Management 19, 98-120 (2000).
22. Grabowski, H. Patents, innovation and access to new pharmaceuticals. J. Intl Econ. Law 5, 849-860 (2002).
23. Grabowski, H. & Vernon, J. Longer patents for increased generic competition in the US: The Waxman-Hatch Act after one decade. PharmacoEconomics 10, S2 110-123 (1996).
24. Centers for Medicare and Medicaid Services. Hospital Outpatient Prospective Payment System Related Information. [online], (2004).
25. P. L. 108-173, Medicare Prescription Drug Improvement and Modernization Act.
26. Centers for Medicare and Medicaid Services. [online], (2004).
27. US Census Bureau [online], (2004).
28. Department of Veterans Affairs [online], (2004).
29. National Conference of State Legislatures. 2001 Prescription Drug Discount, Bulk Purchasing, and Price-Related Legislation. Data for this report was last updated in February 2003. (2003).
30. Watson Wyatt. Retiree Health Benefits: Time to Resuscitate? [online], (2004).
31. US Census Bureau [online], (2003).
32. US Census Bureau, Census 2000 Summary File 1: 1990 Census of Population, General Population Characteristics, United States (1990 CP-1-1).
33. US Census Bureau [online], (2003).
34. [online], (2003).
35. Hansen, R. W. in Issues in Pharmaceutical Economics (ed. Chien, R. I.) 151-187 (Lexington Books, Lexington, 1979)
36. Wiggins, S. N. The Cost of Developing a New Drug (Pharmaceutical Manufacturers Association, Washington, 1987).
37. Woltman, H. R. Reviewing the bidding: R&D costs and profitability of new chemical entities. J. Res. Pharm. Econ. 1, 49-65 (1989).
38. DiMasi, J. A., Hansen, R. W., Grabowski, H. G. & Lasagna, L. Cost of innovation in the pharmaceutical industry. J. Health Econ. 10, 107-142 (1991).
39. US Department of Commerce, Bureau of Economic Analysis. Seasonally adjusted gross domestic product implicit price deflator 2002. [online], (2002).
40. US Congress, Office of Technology Assessment. Pharmaceutical R&D: Costs, Risks, and Rewards OTA-H-522 (US Government Printing Office, Washington, 1993)
41. Public Citizen Congress Watch 2001. Rx R&D Myths: The Case Against the Drug Industry's R&D 'Scare Card' (Public Citizen, Washington, 2001).
42. Public Citizen. Tufts drug study sample is skewed; true figure of R&D costs is likely 7 percent lower. [online], (2002).
43. National Institutes of Health. NIH Contributions to Pharmaceutical Development Administrative Document. (NIH, February 2000).
44. Big pharma likes big trials, Biotech CEO says; Tufts defends R&D estimate. The Pink Sheet June 10, p 17 (2002).
45. Ernst & Young. Pharmaceutical Industry R&D Costs: Key Findings about the Public Citizen Report, August 8, 2001. [online], (2002).
46. PhRMA. The Pharmaceutical Industry's R&D Investment, February 1, 2000 [online], (2002).
47. Tufts Center for the Study of Drug Development. Total cost to develop a new prescription drug, including cost of post-approval research, is $897 million. [online], (2003).
48. Tollman, P. et al. A Revolution in R&D. (Boston Consulting Group, Boston, 2001). [online], (2002).
49. DiMasi, J. A. The value of improving the productivity of the drug development process. PharmacoEconomics 20, S3 1-10 (2002).
50. Foote, S. M. & Etheredge, L. Increasing use of new prescription drugs: a case study. Health Affairs 19, 165-170 (2000).
51. Fuchs, V. R. Health care for the elderly: How much? Who will pay for it? Health Affairs 18, 11-21 (1999).
52. Weisbrod, B. A. & LaMay, C. L. Mixed signals: public policy and the future of health care R&D. Health Affairs 18, 112-125 (1999).
53. Kleinke, J. D. The price of progress: prescription drugs in the health care market. Health Affairs 20, 43-60 (2001).
54. Lichtenberg, F. R. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs 20, 241-251 (2001).
55. Lichtenberg, F. R. Benefits and costs of newer drugs: An update. NBER Working Paper 8996. Cambridge, MA: NBER, June 2002. [online], (2002)
56. Redwood, H. Where is the Pharma Industry Going: Insights for the New Millennium. (PJB Publications, London, 2002).
57. Price Waterhouse Coopers. The Critical Roles of R&D in the Development of New Drugs (PWC, Washington, 2001).
58. National Institutes of Health. NIH Budget, Office of Budget, History of Congressional Appropriations, 1992-2001. Available on-line at www.nih.gov. (8/14/02)
59. US FDA. From Test-tube to Patient: Improving Health Through Human Drugs. (FDA Washington, 1999). [online], (2002).
60. Glover, G. J. Testimony for the Pharmaceutical Research and Manufacturers of America before the Federal Trade Commission and the Department of Justice - Antitrust Division. Washington, March 19, 2002 [online], (2002).
61. Testing drugs in people. [online], (1995).
62. DiMasi, J. Trends in drug development costs, times and risks. Drug Information Assoc. J. 29, 375-384 (1995).